Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Lantern Pharma Inc. LTRN NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
40/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Lantern Pharma Inc. (LTRN) is a Biotechnology company in the Healthcare sector, currently trading at $2.47. It has a SharesGrow Score of 37/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Valuation: LTRN trades at a trailing Price-to-Earnings (P/E) of -0 (S&P 500 average ~25).

Net income is $17.1B (loss), growing at -43363.8%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $79M against $6.5B equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 2.4 (strong liquidity). Debt-to-assets is 0.7%. Total assets: $11.0B.

Analyst outlook: 2 / 3 analysts rate LTRN as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 55/100 (Partial), Income ?/100 (Fail).

LTRN SharesGrow Score Overview

50/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 55/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — LTRN

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
LTRN: +0%/yr revenue is, -43363.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet LTRN: Debt-to-Equity (D/E) ratio 0.01 (conservative), Current ratio is 2.4 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
LTRN: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
55/100
Analyst outlook: 2 / 3 analysts rate LTRN as buy (67%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.11-5.744
Volume213.46K
Avg Volume (30D)557.01K
Market Cap$27.8M
Beta (1Y)1.53
Share Statistics
EPS (TTM)-1.57
Shares Outstanding$10.9M
IPO Date2020-06-11
Employees24
CEOPanna Sharma
Financial Highlights & Ratios
EBITDA$-17.96M
Net Income$-17.12B
Operating Income$-17.98B
Total Cash$10.12B
Total Debt$78.54M
Net Debt$-4.34B
Total Assets$11.04B
Price / Earnings (P/E)-1.6
Analyst Forecast
Rating ConsensusBuy
Analysts Covering3
Buy 67% Hold 33% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS51654W1018

Price Chart

Track all markets on TradingView
LTRN
Lantern Pharma Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
1.11 52WK RANGE 5.74

People Also View

IMNM
IMNM
Immunome, Inc.
$23.39
+2.14%
 CUE
CUE
Cue Biopharma, Inc.
$0.72
+65.37%
 GBIO
GBIO
Generation Bio Co.
$5.34
+0.00%
 LYRA
LYRA
Lyra Therapeutics, Inc.
$0.44
-11.98%
 TFFP
TFFP
TFF Pharmaceuticals, Inc.
$0.07
-60.05%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message